Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Favaretto, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Favaretto, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:1421-1426, 2000
© 2000 European Society for Medical Oncology

research-article

Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in patients with advanced non-small-cell lung cancer

A. Favaretto1,, G. L. Ceresoli2, A. Paccagnella3, F. Barbieri4, A. Bearz5, C. Ghiotto1, F. Oniga3, S. Schiavon6, S. Frustaci5, E. Villa2 and for the Gruppo Studio Tumori Polmonari Veneto (GSTPV)

1Medical Oncology Department, Azienda Ospedaliera Padova Padova, Italy
2Radiochemotherapy Department, IRCCS San Raffaele Milano, Italy
3Medical Oncology Department, Ospedali Civili Riuniti Venezia, Italy
4Medical Oncology Department, Policlinico Universitario Modena Modena, Italy
5Medical Oncology Department, CRO Aviano (PN), Italy
6Medical Oncology Department, Ospedale Civile Vicenza Vicenza, Italy

Correspondence to: A. Paccagnella, MD Medical Oncology Department Ospedali Civili Loc. Castello 30122 Venezia Italy E-mail: jhqa-032{at}mailbox.dsnet.it

BACKGROUND: The combination of paclitaxel (P) and carboplatin (C) is an effective treatment for advanced NSCLC. Gemcitabine (G) is an active new drug. We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently conducted to evaluate the activity and toxicity of PCG.

PATIENTS AND METHODS: Forty-five patients entered the study. Twenty-eight had stage IIIA-B disease, 17 stage IV. In the phase I study, with a fixed dose of C at AUC = 6 on day 1, P was escalated using increments of 25 mg/m2 starting from 175 mg/m2 on day 1 and G with increments of 200 mg/m2 starting from 800 mg/m2 on day 1 and 8.

RESULTS: Fourteen patients entered the phase I study. The MTD was reached at P 200 mg/m2, C AUC = 6 and G 1000 mg/m2. Neutropenic fever and grade 3 diarrhea were the dose limiting toxicities. Thirty-one patients were treated in the phase II study with P 175 mg/m2, C AUC = 6 and G 1000 mg/m2. Response rate was 57% (68% in stage III and 47% in stage IV). Myelosuppression was the main toxicity, with grade 3–4 leukopenia occurring in 35% of cases. Grade 3 anemia was observed in 24% of cases and grade 3–4 thrombocytopenia occurred in 34% of patients. Non-hematological toxicity was mild. Median survival and one-year actuarial survival were 20.5 months and 74% for stage III and 11.5 months and 47% for stage IV.

CONCLUSIONS: PCG is a promising regimen for treating advanced NSCLC. A phase III study comparing PCG to paclitaxel plus carboplatin in advanced NSCLC is ongoing. On the other hand, we are planning to introduce the PCG regimen in the treatment of stage II–III patients in the setting of a multimodality treatment.

carboplatin, chemotherapy, gemcitabine, non-small-cell lung cancer, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. Paccagnella, F. Oniga, A. Bearz, A. Favaretto, M. Clerici, F. Barbieri, A. Riccardi, A. Chella, U. Tirelli, G. Ceresoli, et al.
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-Small-Cell Lung Cancer: Results of a Phase II-III Study
J. Clin. Oncol., February 1, 2006; 24(4): 681 - 687.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.